Gene therapy for pancreatic cancer

Makoto Sunamura, Fuyuhiko Motoi, Masaru Oonuma, Toru Hoshida, Seiki Matsuno

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

In order to develop a new therapeutic intervention for pancreatic cancer, we have examined the effect of gene therapy for pancreatic disease. The transfection of the gene for UPRT, a 5-FU-converting enzyme, resulted in a significant change in the sensitivity of pancreatic cancer cells against 5-FU, resulting in the decrease of the tumor volume disseminated in the abdominal cavity of mice. Although the production levels of vascular endothelial growth factor (VEGF) in pancreatic cancer cell lines are different, anti-angiogenesis gene therapy using a soluble form of VEGF receptor (flt-1) has been demonstrated to be a promising strategy for pancreatic cancer. The transfection efficacy is the crucial point for the success of gene therapy; therefore, it is necessary to develop a vector system for solid tumors. It has been revealed that replication-competent adenoviruses are not only a strong weapon themselves, but are also useful carriers of genes possessing anti-tumor activities as virus vectors specific to tumors without normal p53 function or intact Rb pathway. Determining whether these experimental results are universally true will require clinical trials in the future.

Original languageEnglish
Pages (from-to)398-404
Number of pages7
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume29
Issue number3
Publication statusPublished - 2002 Mar

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Gene therapy for pancreatic cancer'. Together they form a unique fingerprint.

Cite this